New guidance changes access to a prostate cancer blood test, with men over 50 no longer able to obtain it routinely. The updated approach means eligibility is set through clinical guidance and GPs gain greater discretion over who is offered the test.
The reporting highlights strong criticism from the outset, including claims that the policy reduces patient choice and could make earlier detection harder. The Daily Mail frames the change as controversial and quotes Lord Cameron describing it as a “backwards step,” reflecting concerns that the test has been used to help identify prostate cancer sooner. The same coverage also notes that the guidance shifts responsibility toward clinicians to determine whether the test is appropriate for an individual patient.
Across the available account, the central points are the change in who can access the blood test, and the increased role of GPs in decision-making. However, the specific rationale for the guidance and the exact criteria for when the test is offered are not detailed in the provided excerpts.
